Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon

CUTTING-EDGE findings shine new light on mitral valve surgery after failed TEER

Overall, mitral valve surgery after TEER was associated with a 30-day mortality rate of 16.6% and one-year mortality rate of 31.3%.

Thumbnail

Permanent pacemaker implantation after TAVR does not increase risk of death or heart failure

Prior studies have suggested that TAVR patients could face worse outcomes if they require a permanent pacemaker. 

TAVR safe and effective for patients with cirrhosis

Patients with cirrhosis of the liver often undergo TAVR at a younger age, but the outcomes remain strong. 

Thumbnail

Just 3.6% of TAVR procedures in the US performed by women

In addition, researchers noted, there were no female specialists performing TAVR in 19 states. 

FDA approves next-generation solution for PFO closure

The device was designed to treat patients facing a heightened risk of recurrent stroke.

Thumbnail

TAVR and SAVR deliver similar 5-year outcomes for CKD patients

“The choice of intervention in patients with CKD and aortic stenosis is complex and influenced by multiple competing factors," researchers said. 

FDA now investigating potential differences in LAAO outcomes among men and women

Recent research published in JAMA Cardiology caught the agency's attention.

Next-day discharge after TAVR is safe and effective, new meta-analysis confirms

Researchers tracked data from six different studies, focusing on the likelihood of potential issues such as bleeding and vascular complications.

Displaying 537 - 544 of 879
Design by Adaptive Theme